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Aim: To describe health-related quality of life (hrQOL) in adult subjects who had sarcoidosis in
childhood.
Methods: Forty-six children (24 boys), all ethnic Danes 15 years of age with sarcoidosis were
recorded in Denmark in 1979e1994. Three patients were deceased prior to this study. At
follow-up, the 43 surviving adult subjects were invited to complete the short-form health
survey questionnaire SF-36, being completed by 34 subjects (14 men). SF-36 scores were
compared with the scores in the Danish reference population.
Results: At follow-up, 30/34 patients had recovered from sarcoidosis and 4/34 patients had
persistent chronic active disease with impaired lung function. SF-36 scores in all domains were
similar to scores in the reference population; the four patients with chronic active disease had
lower scores in three domains. In the entire series, physical component summary (PCS) score
and mental component summary (MCS) score was similar to the reference population.
Conclusion: Childhood sarcoidosis has a favourable prognosis concerning health status in adult-
hood. The majority of adult subjects had a health status that was indistinguishable from
a healthy reference population.
ª 2008 Elsevier Ltd. All rights reserved.The overall incidence of sarcoidosis in Denmark is 7.2/
100,000 person-years with the peak incidence occurring at
w30 years of age.1 Among Danish children, the incidence
rises from 0.06/100,000 person-years at 4 years of age to10 35 77; fax: þ45 35 45 26 48.
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overall incidence of 0.29/100,000 person-years.1,2 The
natural history of sarcoidosis has been studied most
extensively in adults.1,3e5 A number of studies haveclausbo@dadlnet.dk (C.B. Svendsen), alho@regionsjaelland.dk
.
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using different approaches and questionnaires.6e11
Few papers have reported the natural history and
prognosis of sarcoidosis in children, including a Danish
study.2,12 To our knowledge, there exist no studies, which
have assessed the health-related quality of life (hrQOL) in
adulthood following sarcoidosis in childhood.
The objectives of the present study were to describe the
impact of childhood sarcoidosis on the hrQOL at follow-up
in adulthood using a standardised questionnaire, and to
evaluate the relation to clinical outcome of the disease.
Hence, this work represents cross-sectionally obtained
information adding to the work previously published by two
of the authors.2,12
Material and methods
Study subjects and design
The study was approved by the Regional Ethics Committee
and the recruitment of the patients has been described in
detail previously.2,12 Patients with a diagnosis of sarcoidosis
(nZ 5536) were drawn from the Danish National Patient
Registry in the period 1979e19942; 81 patients were 15
years old and by retrospective chart review, three patients
were excluded: a pair of monozygotic twins who by genetic
analysis proved to have Blau syndrome13 and a Lebanese
boy who was unavailable at follow-up. The diagnosis of
sarcoidosis could be reconfirmed in 46 patients as previ-
ously described.2,12 The series thus comprised 46 patients
(24 males), all ethnic Caucasian Danes.12
Three patients were deceased before this hrQOL study
was initiated: I. A 15 year-old (at onset) boy with pulmonary
sarcoidosis stage II, chronic iridocyclitis, and central
nervous system (CNS) sarcoidosis died in status epilepticus
at 19 years of age. II. A 15-year-old (at onset) girl with
pulmonary sarcoidosis stage II and CNS sarcoidosis with
obstructive hydrocephalus died at 32 years of age from
cerebral infarctions. III. An 11 year-old (at onset) boy with
pulmonary sarcoidosis stage II, iridocyclitis, facial palsy,
peripheral lymphadenitis and hypercalcaemia was treated
with azathioprine for 2 years. He died at 21 years of age
from acute myeloid leukaemia.
Methods
By letter, the 43 surviving subjects were invited to a clinical
follow-up examination in November 1999.12 The letter con-
tained the Danish version of the Medical Outcomes Study 36-
Item short-form health survey questionnaire (SF-36).14,15 At
the follow-up visit, 34 subjects had completed the question-
naire, which was checked by the examiner. The evaluation of
hrQOL was thus performed in a cross-sectional manner.
SF-36 is a generic, standardised health questionnaire
consisting of 36 questions that measure 8 dimensions
(subscales) of health status: physical functioning (PF);
limitations in usual role activities due to physical problems,
role limitation physical (RP); bodily pain (BP); general
health perception (GH); energy and vitality (VT); social
functioning (SF); limitations in usual role activities due to
emotional problems, role limitation emotional (RE); andmental health (MH). In addition there are two summary
scores concerning physical and mental health: physical
component summary score (PCS) and mental component
summary score (MCS). Subscale scores are transformed to
a range from 0 to 100, with a score of 100 indicating the
highest rating of health, i.e., each individual receives
a percentile score that can be compared to ‘‘standardised’’
scores obtained in a control series of approximately 6000
randomly selected Danish men and women representing the
reference population.14
Clinical follow-up comprised pulmonary function tests
and chest X-ray. Pulmonary function tests including diffusion
capacity for carbon monoxide (DLCO) were performed on
a body plethysmograph (Medical Graphics Corp., St. Paul,
Minnesota, USA). Chest X-ray findings were scored in a blin-
ded fashion by the authors (data presented elsewhere12).
Vital status was checked in the Danish Census Registry in
September 2006, where all 43 subjects included in the
study were alive.
Analysis
Differences between non-parametric data were analysed
using Mann-Whitney’s U test and between categorical data
using Pearson’s Chi-square test or Fisher’s exact test as
appropriate. Internal consistency reliability coefficients of
SF-36 data were assessed using Cronbach’s alpha test.
Comparison between patient SF-36 data and control SF-36
data was assessed by a two-sided Student’s t-test for
unpaired data with a correction for inequality of group size
and variance (WelcheSatterthwaite equation). We chose
a significance level of p< 0.05. All analyses were performed
using the SPSS 15.0 data package and Microsoft Excel 2003.
Results
Clinical presentation of sarcoidosis
Clinical, laboratory and radiological features at the onset of
disease have been described previously.2 Table 1 (adapted
from Milman and Hoffmann12) shows the initial presenting
features in the 34 subjects (14 men) who completed the SF-
36 and the 9 subjects (7 men) who did not. There were
significant differences between the groups in the symptom
‘‘dry cough’’ and in chest X-ray disease stage (pZ 0.04 and
pZ 0.01).
Follow-up
Table 2 shows the age at onset of disease, the duration
from onset to follow-up and the age at follow-up in the 34
subjects who completed the SF-36 and the 9 subjects who
did not. There was a significant difference in the age of
onset of disease (pZ 0.03).
Course of childhood sarcoidosis
Among the 34 subjects who completed the SF-36, 28
subjects were healthy and had normal lung function and
chest X-ray. Two men aged 25 and 35 years had recovered
Table 1 Initial cardinal features at onset of disease and
chest X-ray stage in children with sarcoidosis, who at











Skin sarcoidosis 3 NS
Scar sarcoidosis 1 1 NS
Rhinitis, sinusitis 1 1 NS
Cough 2 0.04
Exertional dyspnoea 1 NS




Parotid swelling 1 NS











a Fisher’s exact test (two-sided).
Quality of life after childhood sarcoidosis 915with sequelae, one with chest X-ray infiltrates and one with
permanently impaired unilateral vision; both had normal
lung function and appeared otherwise fit and healthy. Four
subjects aged 18e36 years (one man) had chronic active
pulmonary disease with impaired lung function; in addition,
one woman had central nervous system (CNS) affection
with diabetes insipidus and one woman had chronic intes-
tinal sarcoid disease.
Through the census registry and various health registries
we obtained information of vital status and general health
in the 9 subjects who did not complete SF-36. Seven
subjects were in perfect health. One man aged 36 years hadTable 2 Follow-up of children with sarcoidosis who in







þSF-36 nZ 34 SF-36 nZ 9
Age at onset of
symptoms (y)a
14 (1e16) 15 (13e16) 0.03
Follow-up after onset
of sarcoidosis (y)a
16 (7e23) 17 (10e21) 0.69
Age at follow-up (y)a 28 (18e37) 30 (23e35) 0.14
a Median (range).
b Mann-Whitney’s U test.allergic bronchial asthma and one man aged 36 years had
chronic active CNS sarcoidosis with hypophyseal insuffi-
ciency and diabetes insipidus. This was not significantly
different from the patients having completed the SF-36 (c2
test; pZ 0.75).
SF-36
All 34 subjects completed the SF-36 reliably. This was
confirmed by the high Cronbach’s alpha coefficients for
internal consistency concerning both physical and mental
components as shown in Table 3.
The SF-36 scores are shown in Table 4 and Fig. 1. The SF-
36 scores in adult subjects with childhood sarcoidosis aged
18e37 years were compared with the scores in a reference
population of healthy Danes aged 16e44 years.15 Subjects
with childhood sarcoidosis had significantly higher scores
concerning role limitation physical (RP) (men, pZ 0.01),
role limitation emotional (RE) (men, pZ 0.02) and bodily
pain (BP) (women, pZ 0.02) than reference subjects.
There were no consistent differences in the scores of the
other SF-36 components.
SF-36 in relation to outcome of sarcoid disease
The SF-36 scores in the two men with sequelae from
sarcoidosis did not deviate significantly from the scores in
the 28 completely healthy subjects (data not shown).
However, in the four subjects with chronic active disease
the scores of the categories energy and vitality (VT),
mental health (MH) and mental component summary
score (MCS) were significantly lower compared with the
other 30 patients (Fig. 1; p-values ranging from 0.005 to
0.016).
SF-36 relation to paraclinical variables
In the entire series, we found no association between SF-36
scores and chest X-ray stage, pulmonary function tests or
tobacco smoking. Fourteen patients were treated (3 were
still in treatment) with prednisolone for median 17 months
(range 3e276). There was no association between pred-
nisolone treatment treated as a binary variable (treatment
vs. non-treatment) and SF-36 scores.Table 3 Internal consistency reliability coefficients
(Cronbach’s alpha) of SF-36 questionnaire completed in
adulthood by subjects with childhood sarcoidosis.
Sarcoidosis
(nZ 34)
Dimension of health status
PF RP BP GH VT SF RE MH
Cronbach’s
alpha
0.86 0.94 0.97 0.91 0.92 0.95 0.88 0.91
PFZ physical functioning; RPZ role limitation physical;
BPZ bodily pain; GHZ general health perception; VTZ energy
and vitality; SFZ social functioning; REZ role limitation
emotional; MHZmental health.
Table 4 SF-36 scores (mean SD) in adult subjects aged







Male PF 96 6 96 11 NS
RP 98 7 93 19 0.01
BP 83 28 85 19 NS
GH 81 16 81 16 NS
VT 75 19 73 17 NS
SF 92 16 94 13 NS
RE 98 9 92 21 0.02
MH 87 12 84 13 NS
MCS 56 6 54 7 NS
PCS 54 5 54 6 NS
n 14 1084
Female PF 96 8 94 12 NS
RP 93 20 89 26 NS
BP 89 19 79 22 0.02
GH 78 26 81 17 NS
VT 70 19 69 18 NS
SF 90 15 92 15 NS
RE 85 30 88 26 NS
MH 78 18 80 15 NS
MCS 50 11 53 8 NS
PCS 55 7 53 7 NS
n 20 (18 for
MCS/PCS)
1150
All PF 96 7 95 11 NS
RP 95 16 92 23 NS
BP 86 23 82 21 NS
GH 79 22 81 17 NS
VT 72 19 72 18 NS
SF 91 15 93 14 NS
RE 90 24 91 23 NS
MH 81 16 81 14 NS
MCS 53 10 54 8 NS
PCS 55 6 54 6 NS
n 34 (32 for
MCS/PCS)
2234
PFZ physical functioning; RPZ role limitation physical;
BPZ bodily pain; GHZ general health perception; VTZ energy
and vitality; SFZ social functioning; REZ role limitation
emotional; MHZmental health; PCSZ physical component
summary; MCSZmental component summary.
NSZ not significant.
a Values calculated from the Danish reference material.14
b Student’s t-test, using WelcheSatterthwaite approximation
for unequal variances.
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The overall prognosis of childhood sarcoidosis in Danes is
reasonably good with a recovery rate of 83% (38/46),
a chronic morbidity rate of 11% (5/46) and a mortality rate
of 7% (3/46). Most patients recover within 6 years of disease
onset.12This study describes the health status outcome of
childhood sarcoidosis in a consecutive series of ethnic
Danish patients. The 9 subjects who did not complete SF-36
appeared to be comparable with the 34 subjects who
completed the questionnaire concerning presentation of
disease, age and outcome of disease. The results show that
adult subjects having survived childhood sarcoidosis have
a health status fully comparable to the reference pop-
ulation of healthy Danes matched for gender and age. This
was evident for both the physical and mental subscales as
well as physical (PCS) and mental component summary
scores (MCS). Surprisingly, survivors of childhood sarcoidosis
even sporadically showed significantly higher scores con-
cerning role limitation physical (RP) (men), role limitation
emotional (RE) (men) and bodily pain (BP) (women) than
the reference population (Table 4). This might reflect
a purely statistical coincidence due to the relatively small
sample size or it could be that having a chronic disease in
childhood in some cases improves the persons’ coping
abilities.
In adult patients with sarcoidosis, symptomatic patients
appear to have a poorer health status than those without
symptoms.7 In the present series, subjects who had
recovered from childhood sarcoidosis with slight sequelae
had similar health status as those who had recovered
completely. However, patients with persistent chronic
active disease since childhood had a poorer health status,
especially concerning the energy/vitality and mental
components than those subjects who had recovered
completely, showing that the lack of energy associated
with active disease has a marked effect on health status
(Fig. 1).
We did not find any significant association between
health status and a number of paraclinical variables (chest
X-ray, lung function, prednisolone treatment, etc.), prob-
ably because most subjects were in good health without
clinically significant symptoms, e.g., only four subjects had
impaired lung function (data not shown, but are presented
in detail in Ref. 12).
A few studies of hrQOL have used SF-36 in adult patients
with interstitial lung disease including sarcoidosis6 and in
patients with only sarcoidosis.8 In the series with interstitial
lung disease, median physical component summary (PCS)
score was 32 and median mental component summary
(MCS) score 53.6 Validation of PCS and MCS scores with
physiologic variables showed significant correlations with
pulmonary function tests (FEV1, FVC, DLCO), 6-minute
walking distance and Medical Research Council dyspnoea
score.6
In adult patients with sarcoidosis (79% African-Amer-
ican), there were decrements in all domains of SF-36
compared to healthy persons, the most significant being in
physical functioning (PF), energy and vitality (VT), role
limitation physical (RP) and emotional (RE).9 PCS score in
sarcoidosis patients was 34 12 (mean SD) vs. 45 10 in
control subjects (p< 0.001) and MCS score 45 12 vs.
51 10 in controls (p< 0.001).8 Compared to our data, the
PCS and MCS scores from adult patients with sarcoidosis
were both significantly lower (p< 0.001 for both PCS and
MCS). Cox et al. found significant correlations between PCS
and/or MCS scores and pulmonary function tests (FEV1,
FVC) and dyspnoea score.8 Patients on oral corticosteroids
Figure 1 SF-36 scores in adult survivors of childhood sarcoidosis aged 18e37 years and in healthy Danes aged 16e44 years. Scores
from (nZ 4) patients with chronic active sarcoidosis are also included. These differ significantly from the patients without chronic
disease in the categories Vitality (VT), Mental Health (MH) and Mental Component Summary (MCS).
Quality of life after childhood sarcoidosis 917had significantly lower PCS score than untreated patients.8
We could not reproduce the effect of prednisolone treat-
ment in the present series, though 51% of the children had
been treated with prednisolone for median (range) 1.3
(0.3e23) years.12
In conclusion, childhood sarcoidosis in Danes has a rela-
tively favourable prognosis concerning both survival and
health status in adulthood. Most (65%) of our patients
recovered completely within median (range) 0.7 (0.6e5.9)
years after disease onset. However, there was a mortality
rate of 7% that might reflect the fact that sarcoidosis among
children is relatively rare and can present with diffuse,
extrapulmonary symptoms making it prone to be over-
looked by clinicians giving an unintentional doctor’s delay
in obtaining the diagnosis and hence supplying adequate
treatment. The hrQOL in subjects who have survived
childhood sarcoidosis is as good as in a healthy reference
population.
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